(Q42905560)

English

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalu

scientific article published on 17 September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

peritoneal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Doris M Benbrook

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Jean A Hurteau

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Mark F Brady

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Kathleen M Darcy

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

William P McGuire

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Pamela Edmonds

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Michael L Pearl

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Iouri Ivanov

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Krishnansu S Tewari

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Robert S Mannel

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Kristine Zanotti

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

0 references

publication date

17 September 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

119

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

444-450

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Estrogen signaling: a subtle balance between ER alpha and ER beta

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Integration of the extranuclear and nuclear actions of estrogen

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Estrogen receptor beta: an overview and update

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

THALIDOMIDE AND CONGENITAL ABNORMALITIES

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

VEGF-A and the induction of pathological angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Vascular endothelial growth factor serum concentrations in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

The thalidomide saga

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.002

7 January 2021

Identifiers

10.1016/J.YGYNO.2010.08.002

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846715%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42905560&oldid=1962221257"